Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
- 5 March 2008
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 31 (6), 1155-1159
- https://doi.org/10.1183/09031936.00028708
Abstract
No information is currently available on the influence of injectable second-line drugs on treatment outcomes of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. To investigate this issue, a large series of MDR- and XDR-TB cases diagnosed in Estonia, Germany, Italy and the Russian Federation (Archangels Oblast) between 1999 and 2006 were analysed. All study sites performed drug susceptibility testing for first- and second-line anti-TB drugs, laboratory quality assurance and treatment delivery according to World Health Organization recommendations. Out of 4,583 culture-confirmed cases, 240 MDR- and 48 XDR-TB cases had a definitive outcome recorded (treatment success, death, failure). Among MDR- and XDR-TB cases, capreomycin resistance yielded a higher proportion of failure and death than capreomycin-susceptible cases. Resistance to capreomycin was independently associated with unfavourable outcome (logistic regression analysis: odds ratio 3.51). In the treatment of patients with multidrug-resistant and extensively drug-resistant tuberculosis, resistance to the injectable drug capreomycin was an independent predictor for therapy failure in this cohort. As Mycobacterium tuberculosis drug resistance is increasing worldwide, there is an urgent need for novel interventions in the fight against tuberculosis.Keywords
This publication has 9 references indexed in Scilit:
- Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?European Respiratory Journal, 2008
- Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same ResultsClinical Infectious Diseases, 2008
- Impact of Extensive Drug Resistance on Treatment Outcomes in Non-HIV-Infected Patients with Multidrug-Resistant TuberculosisClinical Infectious Diseases, 2007
- Clinical and operational value of the extensively drug-resistant tuberculosis definitionEuropean Respiratory Journal, 2007
- Origin of the term XDR-TBEuropean Respiratory Journal, 2007
- Worldwide Emergence of Extensively Drug-resistant TuberculosisEmerging Infectious Diseases, 2007
- 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?European Respiratory Journal, 2007
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Impact of Drug-Resistant Mycobacterium tuberculosis on Treatment Outcome of Culture-Positive Cases of Tuberculosis in the Archangel Oblast, Russia, in 1999European Journal of Clinical Microbiology & Infectious Diseases, 2004